Key points are not available for this paper at this time.
Amide Proton Transfer MRI shows clinical benefit in glioma imaging. Clinically useful APTw metrics should be sensitive to changes in amide concentration, a potential marker of tumour proliferation, and insensitive to T1 changes. To investigate sensitivity, simulations and in-vitro studies were performed over a range of amide concentrations and T1 values. In-vitro data included two varied concentration series, with and without T1-maintenance, and a constant concentration T1-vaired series. In-vitro results showed APT* had poor sensitivity, MTRrex was most sensitive to concentration and T1, AREX may overcorrect for T1, and MTRasym appears least sensitive to T1 while remaining sensitive to concentration.
Fothergill et al. (Wed,) studied this question.